Kochar Rajan, Nevah Rubin Moises I, Fallon Michael B
The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Curr Gastroenterol Rep. 2011 Feb;13(1):34-9. doi: 10.1007/s11894-010-0164-6.
Pulmonary vascular complications of liver disease comprise two distinct clinical entities: hepatopulmonary syndrome (HPS-microvascular dilatation and angiogenesis) and portopulmonary hypertension (POPH-vasoconstriction and remodeling in resistance vessels). These complications occur in similar pathophysiologic environments and may share pathogenic mechanisms. HPS is found in 15% to 30% of patients with cirrhosis and its presence increases mortality and the risks of liver transplantation, particularly when hypoxemia is present. Contrast echocardiography and arterial blood gas analysis are required to establish the diagnosis. No medical therapies are available, although liver transplantation is effective in reversing the syndrome. POPH is found in 4% to 8% of patients undergoing liver transplantation evaluation, and the presence of moderate to severe disease significantly increases perioperative transplant mortality. Transthoracic echocardiography is recommended for screening and right-heart catheterization is required to establish the diagnosis. Medical therapies are increasingly effective in improving pulmonary vascular hemodynamics in POPH and may result in better perioperative outcomes.
肝肺综合征(HPS——微血管扩张和血管生成)和门脉高压性肺动脉高压(POPH——阻力血管的血管收缩和重塑)。这些并发症发生在相似的病理生理环境中,可能具有共同的致病机制。15%至30%的肝硬化患者会出现HPS,其存在会增加死亡率以及肝移植风险,尤其是在出现低氧血症时。诊断需要进行对比超声心动图和动脉血气分析。虽然肝移植可有效逆转该综合征,但尚无药物治疗方法。4%至8%接受肝移植评估的患者会出现POPH,中重度疾病的存在会显著增加围手术期移植死亡率。建议进行经胸超声心动图筛查,确诊需要进行右心导管检查。药物治疗在改善POPH的肺血管血流动力学方面越来越有效,可能会带来更好的围手术期结果。